BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors. 2019

İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 06100, Tandoğan-Ankara, Turkey; Erciyes University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 38039, Kayseri, Turkey.

In this study, a series of benzimidazoles bearing thiosemicarbazide chain or triazole and thiadiazole rings were designed and synthesized. Crystal and molecular structure of the compound 5c has been characterized by single crystal X-ray crystallographic analysis. EGFR kinase inhibitory potencies of synthesized compounds were compared with erlotinib in vitro and most of the compounds exhibited significant activities. Cell culture studies were also carried out for selected compounds and 12b was found to be the most active compound. To understand the binding mode of synthesized benzimidazoles, three compounds (12b, 16, 16c) were selected and placed on the binding site of EGFR tyrosine kinase based on their kinase inhibitor potencies and cell culture studies. Docking study indicated that compound 12b showed two-hydrogen bonding interactions with residues of LYS721 and THR830 at the binding pocket.

UI MeSH Term Description Entries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Benzimidazole-Based Derivatives as Apoptotic Antiproliferative Agents: Design, Synthesis, Docking, and Mechanistic Studies.
January 2024, Molecules (Basel, Switzerland),
İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Design, Synthesis and Molecular Docking of Novel Quinazolinone Hydrazide Derivatives as EGFR Inhibitors.
June 2022, Chemistry & biodiversity,
İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Novel sulfonyl thiazolyl-hydrazone derivatives as EGFR inhibitors: Design, synthesis, biological evaluation and molecular docking studies.
April 2022, Bioorganic chemistry,
İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Design, synthesis, anticancer activity and docking studies of novel quinazoline-based thiazole derivatives as EGFR kinase inhibitors.
September 2023, Heliyon,
İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Design, Synthesis, and Biological Evaluation of Benzimidazole Derivatives as Potential Lassa Virus Inhibitors.
February 2023, Molecules (Basel, Switzerland),
İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
June 2018, European journal of medicinal chemistry,
İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Design, molecular docking and synthesis of novel 5,6-dichloro-2-methyl-1H-benzimidazole derivatives as potential urease enzyme inhibitors.
May 2019, Bioorganic chemistry,
İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Design, synthesis and molecular docking studies of imidazole and benzimidazole linked ethionamide derivatives as inhibitors of InhA and antituberculosis agents.
March 2022, Bioorganic & medicinal chemistry letters,
İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Design, Synthesis and Molecular Docking Studies of Pyrazoline Derivatives as PI3K Inhibitors.
January 2024, Combinatorial chemistry & high throughput screening,
İsmail Celik, and Gülgün Ayhan-Kılcıgil, and Berna Guven, and Zümra Kara, and A Selen Gurkan-Alp, and Arzu Karayel, and Arzu Onay-Besikci
Benzimidazole derivatives as tubulin polymerization inhibitors: Design, synthesis and in vitro cytotoxicity studies.
November 2023, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!